This hypothesis may be supported by the current findings that post-transplant progression and relapse rates in patients with CML were comparable between the donor HO-1 A/A or A/T genotype vs. the donor HO-1 T/T genotype, with 33% vs. 33% (p = 0.82) in the high-risk group, and 21% vs. 42% (p = 0.14) in the standard-risk group. Here, HMOX1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.